Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKinsey
AstraZeneca
Colorcon
Dow

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

XYZAL ALLERGY 24HR Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Xyzal Allergy 24hr, and when can generic versions of Xyzal Allergy 24hr launch?

Xyzal Allergy 24hr is a drug marketed by Sanofi Aventis Us and is included in two NDAs. There is one patent protecting this drug.

This drug has thirty patent family members in twenty-four countries.

The generic ingredient in XYZAL ALLERGY 24HR is levocetirizine dihydrochloride. There are thirteen drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.

Drug patent expirations by year for XYZAL ALLERGY 24HR
Recent Litigation for XYZAL ALLERGY 24HR

Identify potential future generic entrants

PTAB Litigation
PetitionerDate
Apotex Inc.2018-12-13

See all XYZAL ALLERGY 24HR litigation

Synonyms for XYZAL ALLERGY 24HR
(-)-Cetirizine Dihydrochloride
(-)-Cetirizine dihydrochloride; 2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid dihydrochloride
(2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
(R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
(R)-Cetirizine diHCl (Levocetirizine diHCl)
(R)-Cetirizine dihydrochloride
[2-[4-[(R)-(4-CHLOROPHENYL)PHENYLMETHYL]-1-PIPERAZINYL]ETHOXY]-ACETIC ACID DIHYDROCHLORIDE
018L870
130018-87-0
2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid dihydrochloride
2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]ethanoic acid dihydrochloride
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
2-[2-[4-[(R)-(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid Dihydrochloride
A806003
AC-549
Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride
AK176131
AKOS015994681
API0000012
API0003160
AT-15143
BC204366
BCP21544
BG0136
CHEMBL1201190
CTK8F2040
D08118
FT-0631130
KS-00000XIF
KS-1177
L0264
Levoceitrizine dihydrochloride
Levocetirizine 2HCl
Levocetirizine diHCl
Levocetirizine dihydrochloride
Levocetirizine dihydrochloride (USAN)
Levocetirizine dihydrochloride [USAN]
Levocetirizine dihydrochloride, >=98% (HPLC)
Levocetirizine HCl
Levocetirizine hydrochloride (JAN)
Levocetirizine Hydrochloride,(S)
Levocetirizine pound>>(R)-Cetirizine (hydrochloride)
LS-186529
MFCD07366507
MolPort-003-983-419
PGLIUCLTXOYQMV-GHVWMZMZSA-N
SCHEMBL144375
SOD6A38AGA
UCB 28556
UCB-28556
UNII-64O047KTOA component PGLIUCLTXOYQMV-GHVWMZMZSA-N
UNII-SOD6A38AGA
Xusal
Xyzal
Xyzal (TN)
Xyzall
Paragraph IV (Patent) Challenges for XYZAL ALLERGY 24HR
Tradename Dosage Ingredient NDA Submissiondate
XYZAL ALLERGY 24HR SOLUTION;ORAL levocetirizine dihydrochloride 209090 2018-01-04

US Patents and Regulatory Information for XYZAL ALLERGY 24HR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us XYZAL ALLERGY 24HR levocetirizine dihydrochloride SOLUTION;ORAL 209090-001 Jan 31, 2017 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us XYZAL ALLERGY 24HR levocetirizine dihydrochloride TABLET;ORAL 209089-001 Jan 31, 2017 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for XYZAL ALLERGY 24HR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0663828 C300085 Netherlands   Start Trial PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 2001C/045 Belgium   Start Trial PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Dow
Baxter
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.